Levine Fred, Itkin-Ansari Pamela
UCSD School of Medicine, Pediatrics, La Jolla, CA, USA.
J Mol Med (Berl). 2008 Mar;86(3):247-58. doi: 10.1007/s00109-007-0259-1. Epub 2007 Oct 6.
Both type I and type II diabetes are characterized by beta-cell loss and dysfunction. Therefore, a major goal of diabetes therapy is to promote the formation of new beta-cells, either in vitro for transplantation or in vivo, i.e., beta-cell regeneration. The question of whether beta-cell regeneration occurs by replication of preexisting beta-cells or by neogenesis from a precursor within the pancreas is a major focus of interest. Lineage-tracing studies have found evidence only for beta-cell replication, while earlier studies based upon the appearance of insulin-positive cells in areas outside of islets formed the basis for the belief that neogenesis from precursors can occur in adult animals. Recently, we found that nonendocrine pancreatic epithelial cells could be induced to undergo endocrine differentiation under the influence of inductive factors from the human fetal pancreas. One possibility is that, similar to models of hepatocyte regeneration, beta-cells can arise either by neogenesis or replication, depending on the particular stimulus. Clearly, understanding the nature and control of beta-cell regeneration is critical for success in efforts to treat diabetes by beta-cell replacement.
I型和II型糖尿病均以β细胞丢失和功能障碍为特征。因此,糖尿病治疗的一个主要目标是促进新β细胞的形成,无论是在体外用于移植还是在体内,即β细胞再生。β细胞再生是通过已存在的β细胞复制还是由胰腺内的前体细胞新生而来,这一问题是主要的研究热点。谱系追踪研究仅发现了β细胞复制的证据,而早期基于胰岛外区域胰岛素阳性细胞出现的研究则成为认为成年动物中前体细胞可发生新生的依据。最近,我们发现非内分泌胰腺上皮细胞在人胎儿胰腺诱导因子的影响下可被诱导进行内分泌分化。一种可能性是,类似于肝细胞再生模型,β细胞可根据特定刺激通过新生或复制产生。显然,了解β细胞再生的本质和调控对于通过β细胞替代治疗糖尿病的成功至关重要。